TLR7/9 antagonists, compound 29 and IRS-954 (immunoregulatory DNA sequence-954), showed therapeutic efficacy in a preclinical murine model of psoriasis and lupus, respectively [149, 150]. The gene discussed is TLR7; the disease is systemic lupus erythematosus.